Related Experiment Video

Updated: Aug 14, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Molecular targeting of growth factor receptor-bound 2 (Grb2) as an anti-cancer strategy

Pathirage G Dharmawardana1, Benedetta Peruzzi, Alessio Giubellino

  • 1Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-1107, USA.

Anti-Cancer Drugs
|December 1, 2005
PubMed

Insights

Growth factor receptor-bound 2 (Grb2) is a key adapter protein in cancer signaling. Targeting Grb2 offers a promising strategy for developing novel anti-cancer therapeutics by disrupting tumor growth and metastasis.

Area of Science:

  • Molecular Biology
  • Oncology
  • Biochemistry

Background:

  • Growth factor receptor-bound 2 (Grb2) is an adapter protein crucial for linking cell surface receptors to the Ras signaling pathway.
  • Grb2 plays a significant role in oncogenesis, cell motility, and angiogenesis, processes vital for tumor progression.
  • Its involvement in multiple cancer-related pathways makes Grb2 a high-priority target for anti-cancer drug development.

Purpose of the Study:

  • To highlight the multifaceted roles of Grb2 in cancer.
  • To underscore the therapeutic potential of targeting Grb2.
  • To discuss the development of novel drug candidates targeting Grb2.

Main Methods:

  • Review of existing literature on Grb2 function and structure-function relationships.
  • Analysis of Grb2's role in oncogenesis, cell motility, and angiogenesis.
  • Evaluation of drug development strategies targeting Grb2 signaling.

Main Results:

  • Grb2's established role in Ras signaling and its implication in oncogenesis.
  • Emerging evidence detailing Grb2's contribution to cell motility and angiogenesis.
  • Successful development of drug candidates with high affinity for Grb2.

Conclusions:

  • Grb2 is a critical mediator in cancer development and progression.
  • Targeting Grb2 presents a viable therapeutic strategy for various human malignancies.
  • Novel Grb2-targeting compounds show promise as rationally designed anti-cancer therapeutics.

More Related Videos

A High-content Imaging Workflow to Study Grb2 Signaling Complexes by Expression Cloning10:52

A High-content Imaging Workflow to Study Grb2 Signaling Complexes by Expression Cloning

Published on: October 30, 2012

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...